Floatz logo

Palifosfamide-Tris

Breast Cancer Nos Metastatic Recurrent

Alaunos TherapeuticsPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

891 Active assets in the Breast Cancer Nos Metastatic Recurrent cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

Palifosfamide-Tris is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
adult central nervous system germ cell tumorDormant
CCC
Indicative ·
48 / 100
View asset →
adult teratomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →